Viatris (VTRS) Competitors

Viatris (NASDAQ:VTRS) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, community ranking, earnings, analyst recommendations, dividends and valuation.

Do analysts rate VTRS or TAK?

Viatris presently has a consensus price target of $11.00, suggesting a potential upside of 3.77%. Takeda Pharmaceutical has a consensus price target of $14.00, suggesting a potential upside of 4.87%. Given Takeda Pharmaceutical's higher possible upside, analysts plainly believe Takeda Pharmaceutical is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33
Takeda Pharmaceutical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Does the media refer more to VTRS or TAK?

In the previous week, Takeda Pharmaceutical had 1 more articles in the media than Viatris. MarketBeat recorded 6 mentions for Takeda Pharmaceutical and 5 mentions for Viatris. Takeda Pharmaceutical's average media sentiment score of 0.27 beat Viatris' score of -0.07 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Takeda Pharmaceutical	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has stronger earnings and valuation, VTRS or TAK?

Takeda Pharmaceutical has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$15.43B	0.82	$54.70M	-$0.06	-176.67
Takeda Pharmaceutical	$28.20B	1.50	$994.06M	$0.55	24.27

Is VTRS or TAK more profitable?

Takeda Pharmaceutical has a net margin of 6.18% compared to Viatris' net margin of -0.37%. Viatris' return on equity of 16.63% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-0.37%	16.63%	7.10%
Takeda Pharmaceutical	6.18%	9.92%	4.71%

Is VTRS or TAK a better dividend stock?

Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 4.5%. Takeda Pharmaceutical pays an annual dividend of $0.26 per share and has a dividend yield of 1.9%. Viatris pays out -800.0% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 47.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Viatris is clearly the better dividend stock, given its higher yield and lower payout ratio.

Do institutionals and insiders believe in VTRS or TAK?

79.9% of Viatris shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 0.3% of Viatris shares are held by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Which has more volatility & risk, VTRS or TAK?

Viatris has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500.

Does the MarketBeat Community believe in VTRS or TAK?

Takeda Pharmaceutical received 79 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 56.82% of users gave Takeda Pharmaceutical an outperform vote while only 35.59% of users gave Viatris an outperform vote.

Company	Underperform	Outperform
Viatris	Outperform Votes 21 35.59%	Underperform Votes 38 64.41%
Takeda Pharmaceutical	Outperform Votes 100 56.82%	Underperform Votes 76 43.18%

Summary

Takeda Pharmaceutical beats Viatris on 11 of the 18 factors compared between the two stocks.